La Jolla’s two main assets are Giapreza, a medication designed to increase blood pressure in patients with septic shock, and Xerava, a treatment for complicated intra-abdominal infections, according to a July 11 press release. The FDA has approved both products for adults.
The transaction is expected to finalize within 30 business days.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
